Dr. Marty Makary, President Trump's nominee to lead the Food and Drug Administration, faced questions from senators about ...
Dr. Marty Makary, Trump's nominee for FDA Commissioner, breezed through his confirmation hearing despite tough questions from Democrats and Republicans.
Martin Makary, President Donald Trump's nominee to run the U.S. FDA, on Thursday promised to convene the agency's vaccine ...
Congress did not reauthorize the rare pediatric disease priority review program at the end of 2024. Advocates say the ripple ...
Dr. Marty Makary will testify before the Senate health committee on Thursday. Lawmakers may press him over staff reductions ...
Q4 2024 Earnings Call Transcript March 5, 2025 EyePoint Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS ...
Marty Makary, Trump’s pick for FDA director, faces his first test as he testifies before the Senate health committee.
A special committee in Albany is investigating what it says are serious and possibly even criminal allegations being made by ...
Harris Beach Murtha attorneys Abbie Fuchs, Dan Strecker, and Alessandra Ash review and analyze key judicial holdings and ...
A BioSpace analysis of all 80 priority review vouchers that have been handed out across the three FDA programs that offer ...
Capricor Therapeutics, Inc.'s Deramiocel receives FDA Priority Review for DMD cardiomyopathy, with a decision by Aug. 2025.
Capricor Therapeutics' shares rose after its biologics license application for deramiocel to treat a form of muscular dystrophy was given priority review by the Food and Drug Administration. Shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback